Prenatal Counseling When the Indication Is a Parental Balanced Translocation
A couple presents at 11 weeks' gestation after two first-trimester miscarriages. Karyotyping of the couple reveals the woman carries a balanced reciprocal translocation, 46,XX,t(4;9)(p15;q22). The couple is of limited financial means, and their insurance covers either chorionic villus sampling (CVS) or amniocentesis, but not both, and does not cover microarray unless ultrasound is abnormal. The woman is 38 and anxious. They ask whether they should "just do the blood test" (cell-free DNA) instead of an invasive test, and whether the translocation means the baby will be affected.
1. How should the counselor explain the reproductive implications of the balanced translocation and the limits of cell-free DNA in this situation?
Read the worked answer
The counselor should explain that a balanced translocation carrier is phenotypically normal but is at increased risk for unbalanced chromosome complements in offspring, typically manifesting as recurrent miscarriage, and, less often, liveborn children with congenital anomalies and developmental differences. The exact risk depends on the chromosomes and breakpoints and on the mode of ascertainment (here, recurrent miscarriage), and the counselor should avoid quoting a single number without referencing the specific translocation. Critically, cell-free DNA screens for common aneuploidies and does not reliably detect unbalanced structural rearrangements involving chromosomes 4 and 9; a normal cfDNA result would not exclude an unbalanced translocation. Therefore cfDNA is not an adequate substitute for diagnostic testing in this couple. The counselor should explain that diagnostic testing (CVS now, or amniocentesis later) with karyotype-and ideally microarray or FISH-is needed to determine the fetal chromosome complement.
2. Given the insurance constraint of one invasive test and no microarray unless ultrasound is abnormal, what testing plan should the counselor recommend, and what are the trade-offs?
Read the worked answer
The counselor should weigh timing against completeness. CVS at 11-13 weeks gives earlier results and earlier options, but a karyotype on CVS can be complicated by confined placental mosaicism and, more importantly, may not fully characterize an unbalanced rearrangement without microarray or FISH; the counselor should ask whether the laboratory can perform FISH or a targeted analysis on the CVS sample within the covered test. Amniocentesis at 15+ weeks is later but yields cleaner results and allows microarray if the insurer's "abnormal ultrasound" criterion is met. Because the couple cannot afford both, the counselor should clarify with the laboratory and insurer exactly what is covered and whether a targeted FISH or microarray can be bundled. The counselor should also discuss that a normal karyotype does not exclude small imbalances detectable only by microarray, and that the couple should decide based on how they would use earlier versus more complete information. The counselor should document the coverage limitation and advocate for the diagnostically appropriate test.
3. The woman asks, "Does the translocation mean the baby will be affected?" How should the counselor answer?
Read the worked answer
The counselor should answer directly that it does not mean the baby will be affected, but that it raises the chance of a chromosome imbalance. A conception can inherit a normal complement, a balanced translocation like the mother's (carrier, typically unaffected), or an unbalanced complement (which may cause miscarriage or, if liveborn, health and developmental problems). The counselor should explain that most unbalanced conceptions result in miscarriage, which is consistent with the couple's history, but that the possibility of a liveborn affected child is why diagnostic testing is offered. The counselor should avoid false reassurance and avoid alarm, use the couple's own history to make the explanation concrete, and offer genetic counseling follow-up and written materials. The counselor should also note that the risk estimate is specific to this translocation and that a genetics/cytogenetics consultation can refine it.